ӳ��ý

Genetic Variation Augments Incretin Resistance and Influences Response to a Sulfonylurea and Metformin: The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH).

Srinivasan S, Kaur V, Chamarthi B, et al. Genetic Variation Augments Incretin Resistance and Influences Response to a Sulfonylurea and Metformin: The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH). Diabetes Care. 2018;41(3):554-561. doi:10.2337/dc17-1386

Metabolomics signatures associated with an oral glucose challenge in pregnant women.

Gelaye B, Clish CB, Denis M, et al. Metabolomics signatures associated with an oral glucose challenge in pregnant women. Diabetes Metab. 2019;45(1):39-46. doi:10.1016/j.diabet.2018.01.004

Metabolomics insights into early type 2 diabetes pathogenesis and detection in individuals with normal fasting glucose.

Merino J, Leong A, Liu CT, et al. Metabolomics insights into early type 2 diabetes pathogenesis and detection in individuals with normal fasting glucose. Diabetologia. 2018;61(6):1315-1324. doi:10.1007/s00125-018-4599-x

Race-ethnic differences in the association of genetic loci with HbA1c levels and mortality in U.S. adults: the third National Health and Nutrition Examination Survey (NHANES III).

Grimsby JL, Porneala BC, Vassy JL, et al. Race-ethnic differences in the association of genetic loci with HbA1c levels and mortality in U.S. adults: the third National Health and Nutrition Examination Survey (NHANES III). BMC Med Genet. 2012;13:30. doi:10.1186/1471-2350-13-30

Genetic inactivation of ANGPTL4 improves glucose homeostasis and is associated with reduced risk of diabetes.

Gusarova V, O’Dushlaine C, Teslovich TM, et al. Genetic inactivation of ANGPTL4 improves glucose homeostasis and is associated with reduced risk of diabetes. Nat Commun. 2018;9(1):2252. doi:10.1038/s41467-018-04611-z

Identification and functional characterization of G6PC2 coding variants influencing glycemic traits define an effector transcript at the G6PC2-ABCB11 locus.

Mahajan A, Sim X, Ng HJ, et al. Identification and functional characterization of G6PC2 coding variants influencing glycemic traits define an effector transcript at the G6PC2-ABCB11 locus. PLoS Genet. 2015;11(1):e1004876. doi:10.1371/journal.pgen.1004876

Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones.

Maianti JP, McFedries A, Foda ZH, et al. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature. 2014;511(7507):94-8. doi:10.1038/nature13297

Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility.

Wessel J, Chu AY, Willems SM, et al. Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. Nat Commun. 2015;6:5897. doi:10.1038/ncomms6897

Targeting the pancreatic β-cell to treat diabetes.

Vetere A, Choudhary A, Burns SM, Wagner BK. Targeting the pancreatic β-cell to treat diabetes. Nat Rev Drug Discov. 2014;13(4):278-89. doi:10.1038/nrd4231

Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis.

Voight BF, Scott LJ, Steinthorsdottir V, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42(7):579-89. doi:10.1038/ng.609